evidence and practice
Should men on long-term androgen-deprivation therapy for prostate cancer be screened and monitored for osteoporosis?
Louise Cunningham Oncology nurse specialist, The Sandra Chapman Centre, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, England
Androgen-deprivation therapy is the main long-term treatment for men with advanced prostate cancer. A side effect of this therapy is secondary osteoporosis with associated reduction in bone mineral density, which increases the risk of fragility fractures and reduces patients’ quality of life. Screening and monitoring for osteoporosis in this patient group is variable, and can result in delayed prevention and treatment. This article reviews the literature on screening and monitoring for osteoporosis to consider the need for implementation of local guidelines for this patient group. It recommends implementation of screening and monitoring guidelines as part of clinical practice and holistic needs assessment, as there are clear benefits for patients, their families and NHS resources.
Cancer Nursing Practice. doi: 10.7748/cnp.2018.e1511Citation
Cunningham L (2018) Should men on long-term androgen-deprivation therapy for prostate cancer be screened and monitored for osteoporosis? Cancer Nursing Practice. doi: 10.7748/cnp.2018.e1511Peer review
This article has been subject to external double-blind peer review and checked for plagiarism using automated softwareCorrespondence
Published online: 08 August 2018
Want to read more?
Subscribe for unlimited access
Try 1 month’s access for just £1 and get:
- Full access to the website and the online archive
- Bi-monthly digital edition
- RCNi Portfolio and interactive CPD quizzes
- RCNi Learning with 200+ evidence-based modules
- 10 articles a month from any other RCNi journal
Already subscribed? Log in
Alternatively, you can purchase access to this article for the next seven days. Buy now